Adaptin Bio, Inc. is a biopharmaceutical company focused on developing innovative therapies for brain cancers and CNS disorders using proprietary technologies.

# Company Overview: Adaptin Bio, Inc.

## Business Description
Adaptin Bio, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to effectively treat brain cancers and other central nervous system (CNS) disorders. The company leverages proprietary technology designed to enhance the transfer of therapeutics across biological barriers, particularly the blood-brain barrier (BBB), using the human immune system to target and deliver therapeutics precisely to specific cells like cancer cells.

### Key Technologies
- **BRiTE Technology**: Stands for Brain Bispecific T-cell Engager, a novel approach that combines T-cell targeting agents with activated T cells to deliver therapeutics to challenging sites, such as brain tumors.
- **Lead Product Candidate**: APTN-101 is engineered to target the epidermal growth factor receptor variant III (EGFRvIII), which is specifically expressed on malignant tumor cells, especially within glioblastoma.

## Mission
To be a global leader in transforming cancer treatment paradigms and addressing significant unmet medical needs through innovative therapeutic solutions utilizing cutting-edge biopharmaceutical technologies.

## Operations
- **Primary Activities**: The company is focused on advancing its lead candidate APTN-101 through clinical trials, with plans to expand into broader therapeutic areas, including autoimmune diseases and cardiovascular disorders.
- **Operational Focus**: The clinical development of APTN-101 and pursuing additional product candidates through preclinical studies and investigational new drug (IND) applications.

## Financials
- **Employees**: As of March 31, 2025, Adaptin Bio has four employees. 
- **Revenue**: The company has not generated any revenue since its inception. 
- **Income**: For the fiscal year ending December 31, 2024, the company reported a net loss of $161,160, an increase from a loss of $85,593 in the previous year (2023).
- **Cash Position**: As of December 31, 2024, the company held $12,619 in cash, an increase from $380 in the previous year.
- **Current Liabilities**: Total current liabilities were $286,676 as of December 31, 2024.

## Business Strategy
- **Product Development**: The company aims to complete necessary regulatory filings and transition into phases of clinical development for APTN-101 and explore other therapeutic indications.
- **Capital Raising**: Adaptin Bio anticipates needing additional funding to support operations, as current cash reserves are not sufficient to cover anticipated expenditures for the next twelve months.
- **Strategic Partnerships**: Engage potential collaborative opportunities for further therapeutic advancements and market access.

## Customers and Market
- As a developing pharmaceutical entity, Adaptin Bio does not have an established customer base yet since the primary focus is on the development and clinical trials of its product candidates. The success of APTN-101 could pave the way for attracting collaborative partners and broader patient populations once it receives necessary approvals and reaches the market.

This detailed overview reflects Adaptin Bio's commitment to addressing CNS disorders and potential future growth within the biopharmaceutical industry.

Unite Acquisition 1 Corp. is a blank check company focused on acquiring an existing business to operate as a publicly traded entity, with no active operations or revenue since inception.

# Company Overview: Unite Acquisition 1 Corp.

**Incorporation and Purpose:**
- **Date of Incorporation:** March 10, 2022
- **Location:** Delaware
- **Business Type:** Blank check company and shell company
- **Purpose:** To investigate and acquire an existing company, offering the perceived advantages of being publicly held.

## Business Activities:
- The company has **not conducted any active operations** since its inception. Its current activities are primarily focused on organizational efforts and obtaining initial financing.
- The company **has not negotiated or entered into any letters of intent** concerning potential target businesses.
- Target acquisition candidates are not restricted by **industry, business type, or geographical location**.

## Financial Overview:
- **Fiscal Year End:** December 31
- **Cash Balance:** 
  - As of December 31, 2023: **$380**
  - As of December 31, 2022: **$500**
- **Total Assets:** 
  - As of December 31, 2023: **$380**
  - As of December 31, 2022: **$500**
- **Total Liabilities:**
  - As of December 31, 2023: **$113,277**
  - As of December 31, 2022: **$27,804**
- **Accumulated Deficit:**
  - As of December 31, 2023: **-$113,397**
  - As of December 31, 2022: **-$27,804**
  
## Revenue and Income:
- **Revenue:**
  - The company has generated **no revenue** since inception.
  
- **Net Loss:**
  - For the year ended December 31, 2023: **-$85,593**
  - For the period from inception to December 31, 2022: **-$27,804**

## Staffing:
- **Employees:** 
  - The company has **no employees** apart from its management. 
- **Management:**
  - Nathan P. Pereira serves as President, CEO, CFO, Secretary, and Director.

## Customers and Market Activity:
- The company currently has **no customers** as it has not commenced active operations or engaged in any business activities.

## Future Plans:
- The company plans to locate suitable acquisition candidates and may incur costs related to filing reports, conducting due diligence, and consummating a business combination.
- It is anticipated that ongoing costs will be funded through advances from Lucius Partners, the sole stockholder.

## Regulatory and Compliance:
- The company qualifies as an "emerging growth company" and "smaller reporting company", providing it exemptions from various reporting requirements.

In summary, Unite Acquisition 1 Corp. is primarily focused on identifying and acquiring a target company to enable it to operate as a publicly traded entity. As a blank check and shell company, it has no operational revenue, minimal cash on hand, and is reliant on its sole stockholder for financial support.

ADAPTIN BIO, INC.

10-K / April 15, 2025

10-K / April 1, 2024

10-K / April 15, 2025

Company Overview: Adaptin Bio, Inc.

Business Description

Key Technologies

Mission

Operations

Financials

Business Strategy

Customers and Market